The case for allowing steroids in sports rests on several interconnected arguments: that the current ban is inconsistently enforced, that genetic advantages already create massive inequalities between athletes, that prohibition pushes drug use underground where it becomes more dangerous, and that a regulated approach could actually protect athletes better than the status quo. These aren’t fringe ideas. Bioethicists at Oxford, sports scientists, and even some former anti-doping officials have raised serious questions about whether the current system is as fair or effective as it claims to be.
Genetic Advantages Already Dwarf Drug Effects
One of the strongest arguments for allowing steroids is that elite sport already tolerates enormous biological inequality. Michael Phelps’s wingspan, a 7-foot basketball player’s height, and a sprinter’s proportion of fast-twitch muscle fibers are all genetic advantages that no amount of training can replicate. Yet we celebrate these gifts rather than regulating them.
The genetic lottery goes deeper than body size. Certain gene variants increase respiratory capacity by altering how the body processes oxygen. Others boost stamina through more efficient energy production during exercise. Some athletes carry variations in testosterone receptor genes that give them, as researchers put it, more “bang for the androgen buck” from the same amount of testosterone as someone without those polymorphisms. In practical terms, two athletes with identical testosterone levels can get dramatically different muscle-building effects from the same hormone, purely because of their DNA.
This creates an uncomfortable parallel. As one bioethicist framed it, “taking an excess of testosterone is cheating,” while “producing an excess of testosterone is a genetic advantage.” For athletes whose bodies naturally produce unusually high levels of performance-enhancing hormones, the effect is as though they have taken steroids, except they haven’t broken any rules. If sport already accepts these biological inequalities as part of competition, the argument goes, then banning external substances that produce similar effects is philosophically inconsistent.
The Level Playing Field Argument
Elite sport is not the meritocracy it presents itself as. Athletes from wealthy nations have access to altitude training camps, hypoxic sleeping chambers, cutting-edge biomechanical analysis, personal nutritionists, and recovery technologies that athletes in developing countries simply cannot afford. These tools are all legal and all performance-enhancing.
Bioethicists including Julian Savulescu at Oxford have argued that allowing performance-enhancing drugs could actually narrow this gap. Illegal EPO, for instance, is far more affordable for a third-world athlete than a legal hypoxic training facility that simulates altitude exposure. Both achieve the same physiological result: more red blood cells and better oxygen delivery. But one is banned and the other is encouraged. Removing the prohibition on substances, this argument holds, would make the rules equally applied to everyone rather than favoring those with the deepest pockets for legal performance technology.
There’s also the simple math of cheating. When some athletes dope and others don’t, honest competitors are penalized. Allowing regulated use would, as Oxford’s practical ethics researchers put it, “narrow the gap between the cheaters and the honest athletes” by eliminating the advantage of breaking rules.
Prohibition Makes Drug Use More Dangerous
Athletes who use steroids under the current system do so in secret, often relying on black-market products with no quality control. A systematic review published in BMC Public Health found widespread problems with fake and adulterated steroids sold on the black market, including products that contained the wrong substance entirely or were contaminated. Despite the known risks, there is currently no published evidence on the health outcomes of controlled, physician-supervised testosterone use through proper healthcare channels for athletes. That gap exists precisely because the ban prevents such research from being conducted.
The harm reduction argument mirrors what public health experts have learned from drug policy more broadly: prohibition doesn’t eliminate use, it just makes use more dangerous. Athletes who fear career-ending sanctions won’t tell their doctors what they’re taking, won’t get blood work monitored, and won’t seek help when something goes wrong.
The Enhanced Games, a proposed competition that openly permits performance-enhancing drugs, has tried to address this directly. Their model doesn’t allow all substances without limits. Instead, drugs are only permitted under medical supervision to prevent overuse or complications from inherited health conditions. Athletes’ health is continuously evaluated. Leading international doping scientists recommended this kind of constant health monitoring to the International Olympic Committee over fifteen years ago, but the recommendation was never adopted within the current prohibition framework.
The Anti-Doping System Has Serious Flaws
The World Anti-Doping Agency uses three criteria to decide whether a substance belongs on its prohibited list. A substance needs to meet just two of the following: it enhances or has the potential to enhance performance, it represents an actual or potential health risk, or it violates the “spirit of sport.” That third criterion is subjective and difficult to define consistently. Caffeine enhances performance. So does creatine. Both are legal. The line between acceptable and unacceptable enhancement is, in many cases, arbitrary.
Testing itself remains unreliable. The Athlete Biological Passport, which tracks blood markers over time to flag suspicious changes, has known limitations. Research has shown that normal physiological variations from exercise, competition, altitude exposure, and metabolic differences can mimic the signatures of doping. This creates a real risk of false positives, where clean athletes are flagged, and false negatives, where micro-dosing athletes slip through undetected. A 2011 study noted that the mixed results around the stability of blood variables used in the passport system could lead to misinterpreted results with “dramatic consequences” at major events.
Meanwhile, the Therapeutic Use Exemption system already allows some athletes to use banned substances legally. At the Olympic and Paralympic Games between 2016 and 2022, less than 1% of Olympic athletes and about 2.76% of Paralympic athletes competed with valid TUEs. The numbers are small, but the principle matters: the system already acknowledges that banned substances have legitimate uses and grants exceptions on a case-by-case basis. Critics argue this creates a two-tier system where athletes with access to sympathetic physicians and sophisticated medical documentation can obtain legal permission for substances their competitors cannot use.
Recovery and Athlete Longevity
Beyond performance, anabolic steroids show genuine potential for helping athletes recover from injuries. In animal studies on muscle contusion injuries, muscles treated with anabolic steroids were significantly stronger than control muscles by day 14, showing better-organized fiber architecture and faster recovery of force-generating capacity. Corticosteroids, by contrast, left muscles weaker than untreated controls by day 7 and totally degenerated by day 14.
Professional athletes already undergo surgeries and rehabilitation protocols that push the boundaries of medical intervention. Platelet-rich plasma injections, stem cell therapies, and other advanced recovery methods are all permitted. If the goal of anti-doping policy is to protect athlete health, allowing medically supervised anabolic support during injury recovery could actually reduce career-ending injuries and the chronic pain that follows many athletes into retirement.
What a Regulated Model Could Look Like
Proponents of legalization rarely argue for a free-for-all. The more sophisticated position involves creating a regulated framework with dosage limits, mandatory medical monitoring, and transparency. Athletes would disclose what they’re taking, physicians would track cardiovascular markers, liver function, and hormonal balance, and sports organizations would set upper thresholds for health-relevant biomarkers rather than blanket bans on substances.
This model shifts the focus from catching cheaters to protecting health. Instead of spending hundreds of millions on detection and enforcement (WADA’s budget and the national anti-doping agencies it coordinates represent a massive global infrastructure), resources could go toward medical oversight. Athletes would no longer need to hide their use, making the entire system more transparent.
The counterarguments are real: coercion pressure on young athletes, unknown long-term health effects of normalized use, and the philosophical question of whether sport should celebrate natural human capacity. But the case for legalization isn’t built on ignoring those concerns. It’s built on the observation that the current system already fails to deliver on its promises of fairness, safety, and a level playing field, and that a different approach might do better on all three counts.